Pfizer submits clinical data to FDA for vaccine booster shot approval
Category: #health  By Mateen Dalal  Date: 2021-08-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

Pfizer submits clinical data to FDA for vaccine booster shot approval

Leading vaccine developers, Pfizer and BioNTech have recently submitted primary stage clinical data to the U.S. FDA (Food and Drug Administration) as a part of their efforts to authorize booster vaccine shot for COVID-19 for everyone aged above 16, including ones with weak immune system.

In a press release, the companies said that volunteers in the clinical trial received a third dosage of the two-dose vaccine roughly eight to nine months following their second shot. In the trial, the vaccine booster dose generated higher neutralizing antibodies against the original coronavirus strain and the beta and delta variants.

Pfizer CEO, Albert Bourla says that the data they have seen suggests that third dose of vaccines produces higher antibodies than those produced after both doses. As a result, they are thrilled to submit this application to the FDA as they continue to collaborate to meet the pandemic's growing challenges.

According to the firm, late-stage research results evaluating the third dose are anticipated soon and will be submitted to the FDA and other regulatory agencies worldwide.

The drug makers announcement comes after the federal health officials approved using Covid booster shots on Americans with weak immune system, which comprises HIV and cancer patients and people who have undergone organ transplants.

The new data from the U.S. suggests that immune-compromised individuals do not produce enough immune response after getting jabbed with two doses of the Covid vaccine.

Although, Federal health officials still don’t recommend the booster dose for the general public, White House chief medical advisor, Dr. Anthony Fauci has indicated that every individual would require a booster shot at some point.

Similarly, Covid vaccine makers, including Pfizer and Moderna, have said that every individual will need a booster shot and possibly extra doses each year like seasonal flu.

Source Credit - https://www.cnbc.com/2021/08/16/covid-vaccine-booster-shot-pfizer-submits-data-to-fda-for-approval.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Health insurer Alan acquires Jour to enter the mental health market
Health insurer Alan acquires Jour to enter the mental health market
By Mateen Dalal

Alan, a health insurance startup based in France, has acquired American digital behavioral health firm, Jour for $20 million. The acquisition has assisted the French health insurer to launch its new digital health service, Alan Mind, helping it ...

WAVE Electronics adds CYNC™ Smart Home solutions to its portfolio
WAVE Electronics adds CYNC™ Smart Home solutions to its portfolio
By Mateen Dalal

South Korean consumer equipment firm, WAVE Electronics has recently formed an alliance with home automation company, Savant Systems, Inc. to provide CYNC™ smart home solutions to its contractors, custom installation professionals, and builders ...

WardWizard Innovations & Mobility to invest $20Mn in EV business
WardWizard Innovations & Mobility to invest $20Mn in EV business
By Mateen Dalal

Indian electric vehicle manufacturer, WardWizard Innovations and Mobility have expressed plans to spend INR 150 crore (USD 20 million) in the coming six months in its EV business, as it seeks to ramp up technology and infrastructure, among other thin...